全文获取类型
收费全文 | 2230篇 |
免费 | 133篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 22篇 |
妇产科学 | 54篇 |
基础医学 | 338篇 |
口腔科学 | 22篇 |
临床医学 | 223篇 |
内科学 | 624篇 |
皮肤病学 | 37篇 |
神经病学 | 153篇 |
特种医学 | 49篇 |
外科学 | 288篇 |
综合类 | 24篇 |
一般理论 | 1篇 |
预防医学 | 126篇 |
眼科学 | 24篇 |
药学 | 140篇 |
中国医学 | 6篇 |
肿瘤学 | 219篇 |
出版年
2023年 | 35篇 |
2022年 | 14篇 |
2021年 | 72篇 |
2020年 | 65篇 |
2019年 | 52篇 |
2018年 | 84篇 |
2017年 | 43篇 |
2016年 | 49篇 |
2015年 | 68篇 |
2014年 | 94篇 |
2013年 | 108篇 |
2012年 | 165篇 |
2011年 | 163篇 |
2010年 | 94篇 |
2009年 | 69篇 |
2008年 | 139篇 |
2007年 | 143篇 |
2006年 | 122篇 |
2005年 | 133篇 |
2004年 | 115篇 |
2003年 | 89篇 |
2002年 | 90篇 |
2001年 | 28篇 |
2000年 | 22篇 |
1999年 | 22篇 |
1998年 | 9篇 |
1997年 | 13篇 |
1996年 | 10篇 |
1995年 | 7篇 |
1993年 | 9篇 |
1992年 | 16篇 |
1991年 | 12篇 |
1990年 | 16篇 |
1989年 | 20篇 |
1988年 | 15篇 |
1987年 | 12篇 |
1986年 | 11篇 |
1985年 | 10篇 |
1981年 | 6篇 |
1980年 | 8篇 |
1979年 | 11篇 |
1978年 | 9篇 |
1977年 | 8篇 |
1976年 | 8篇 |
1975年 | 7篇 |
1974年 | 7篇 |
1972年 | 9篇 |
1970年 | 12篇 |
1969年 | 6篇 |
1967年 | 7篇 |
排序方式: 共有2371条查询结果,搜索用时 15 毫秒
1.
2.
Polyakov Andrey P. Mordovskiy Alexander V. Ratushnyy Mikhail V. Rebrikova Irina V. 《Oral and maxillofacial surgery》2021,25(2):271-277
Oral and Maxillofacial Surgery - Presently, the functional reconstruction of the tongue in patients after subtotal or total glossectomy with the removal of the oral floor muscles and spearing of... 相似文献
3.
Cancer and Metastasis Reviews - 相似文献
4.
5.
The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies
Mahamat Babagana Julia V. Kichina Hannah Slabodkin Sydney Johnson Alexei Maslov Lorin Brown Kristopher Attwood Mikhail A. Nikiforov Eugene S. Kandel 《Molecular carcinogenesis》2020,59(1):5-14
The activation of oncogenic mitogen-activated protein kinase cascade via mutations in BRAF is often observed in human melanomas. Targeted inhibitors of BRAF (BRAFi), alone or as a part of a combination therapy, offer a significant benefit to such patients. Unfortunately, some cases are initially nonresponsive to these drugs, while others become refractory in the course of treatment, underscoring the need to understand and mitigate the underlying resistance mechanisms. We report that interference with polo-like kinase 3 (PLK3) reduces the tolerance of BRAF-mutant melanoma cells to BRAFi, while increased PLK3 expression has the opposite effect. Accordingly, PLK3 expression correlates with tolerance to BRAFi in a panel of BRAF-mutant cell lines and is elevated in a subset of recurring BRAFi-resistant melanomas. In PLK3-expressing cells, R406, a kinase inhibitor whose targets include PLK3, recapitulates the sensitizing effects of genetic PLK3 inhibitors. The findings support a role for PLK3 as a predictor of BRAFi efficacy and suggest suppression of PLK3 as a way to improve the efficacy of targeted therapy. 相似文献
6.
Antaki Fares Coussa Razek Georges Mikhail Mikel Archambault Cyril Lederer David E. 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2020,258(12):2681-2690
Graefe's Archive for Clinical and Experimental Ophthalmology - To investigate the prognostic value of peripheral retinal nonperfusion in patients with diabetic retinopathy using ultra-widefield... 相似文献
7.
Gamal Shiha Nasser Mousa Reham Soliman Nabiel NNH Mikhail Mohamed Adel Elbasiony Mahmoud Khattab 《Journal of viral hepatitis》2020,27(7):671-679
Liver cirrhosis is an important risk factor for hepatocellular carcinoma. The reported annual incidence of HCC is about 3%‐8% in CHC cirrhotic patients. Based on the Cochrane systematic review, there was no clear evidence, on the long‐term clinical effects of DAAs in patients achieving SVR, as regard liver cirrhosis‐related HCC incidence. The aim of the study was to determine the incidence of HCC in chronic hepatitis C patients genotype IV with liver cirrhosis and advanced liver fibrosis after achieving SVR following DAA treatment in a prospective large cohort of HCV patients with long follow‐up. This was a prospective observational cohort study including 2372 CHC patients with advanced liver fibrosis or cirrhosis receiving DAA therapy in outpatient clinics at the Egyptian Liver Research Institute and Hospital since January 2015. Liver fibrosis was assessed using transient elastography. Abdominal ultrasonography and AFP measurement were done at baseline and follow‐up visits every 6 months, in addition to triphasic abdominal MSCT when needed. Patients were followed up after achieving SVR12 for at least 12 months. HCC developed in 109 cases during the follow‐up period (mean 23.60 ± 8.25 months). Overall HCC incidence was 2.338/100 PY, 95% CI = 1.942‐2.814. In patients with cirrhosis, the incidence of HCC was 2.917/100 PY, 95% CI = 2.407‐3.535, while in patients with advanced liver fibrosis the incidence of HCC was 0.664/100 PY, 95% CI = 0.333‐1.326. In conclusion, the incidence of HCC was reduced in chronic hepatitis C genotype 4 patients with liver cirrhosis (F4) and advanced hepatic fibrosis (F3) who achieved SVR following DAA therapy. 相似文献
8.
Kieran F. Docherty Pardeep S. Jhund Olof Bengtsson David L. DeMets Silvio E. Inzucchi Lars Kber Mikhail N. Kosiborod Anna Maria Langkilde Felipe A. Martinez Marc S. Sabatine Mikaela Sjstrand Scott D. Solomon John J.V. McMurray 《Diabetes care》2020,43(11):2878
OBJECTIVETo determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT).RESEARCH DESIGN AND METHODSWe examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death.RESULTSIn the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58–0.88] vs. 0.86 [0.60–1.23]; interaction P = 0.39) and across GLT classes.CONCLUSIONSIn DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF. 相似文献
9.
Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized,double‐blind,placebo‐controlled trial 下载免费PDF全文